NY State Senate Bill 2023-S8959

Current Bill Status - In Senate Committee Health Committee

Introduced
- In Committee Assembly
- In Committee Senate
- On Floor Calendar Assembly
- On Floor Calendar Senate
- Passed Assembly
- Passed Senate
Delivered to Governor
Signed By Governor

Please enter your contact information

First Name

Last Name

Email Address

A valid email address is required.

Home address is used to determine the senate district in which you reside. Your support or opposition to this bill is then shared immediately with the senator who represents you.

Optional services from the NY State Senate:

Create an account. An account allows you to officially support or oppose key legislation, sign petitions with a single click, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Include a custom message for your Senator? (Optional)

Enter a message to your senator. Many New Yorkers use this to share the reasoning behind their support or opposition to the bill. Others might share a personal anecdote about how the bill would affect them or people they care about.

Actions

View Actions

	Assembly Actions - Lowercase Senate Actions - UPPERCASE
Apr 03, 2024	referred to health

2023-S8959 (ACTIVE) - Details

Current Committee:: Senate Health
Law Section:: Social Services Law
Laws Affected:: Amd §365-a, Soc Serv L; amd §§3216, 3221 & 4303, Ins L

2023-S8959 (ACTIVE) - Summary

Requires comprehensive coverage for treatment of obesity, including coverage for prevention and wellness, nutrition counseling, intensive behavioral therapy, bariatric surgery, and FDA-approved anti-obesity medication.

2023-S8959 (ACTIVE) - Sponsor Memo

                                 
BILL NUMBER: S8959

SPONSOR: COONEY
 
TITLE OF BILL:

An act to amend the social services law and the insurance law, in
relation to requiring comprehensive coverage for treatment of obesity

 
PURPOSE OR GENERAL IDEA OF BILL:

This legislation will expand access to services and medications to treat
obesity.

 
SUMMARY OF PROVISIONS:

Section 1 adds a new paragraph to subdivision (2) of section 365-a of
the social services law, requiring state sponsored health plans to
provide comprehensive coverage for the treatment of obesity.

Section 2 adds a new paragraph 39 to subsection (i) of section 3216 of
the insurance law, requiring commercial insurance policies to provide
comprehensive coverage for the treatment of obesity.

Section 3 adds a new paragraph 22 to subsection (1) of section 3221 of
the insurance law, applying these same provisions to group or blanket
policies that provide medical, major medical, or similar comprehensive-
type coverage.

Section 4 adds a new subsection (vv) to section 4303 of the insurance
law, applying these same provisions to group or blanket policies that
provide medical, major medical, or similar comprehensive-type coverage.

Section 5 is the effective date.

 
JUSTIFICATION:

The rate of obesity has reached epidemic proportions in New York State,
affecting approximately 2 out of every 3 adult New Yorkers.  According
to the Centers for Disease Control and Prevention, obesity is a serious
condition that increases the risk of chronic diseases such as heart
disease, stroke, type 2 diabetes, some cancers, and even death. Addi-
tionally, obesity is associated with substantial health care expendi-
tures, costing New York's already overburdened healthcare system over
$10 million annually.

Furthermore, disparities in obesity rates are significant across racial
and ethnic groups, with its prevalence being highest among adults who
are Black and Hispanic. These inequities underscore the need to address
social determinants of health and remove barriers to comprehensive
health care access.

Recent advances in understanding the underlying mechanisms of obesity
and drug therapy to treat obesity have provided the medical community
with additional safe and effective treatment options.

To improve overall health and lower the risk of secondary complications
caused by obesity, it is critical that public policy ensure New Yorkers
have access to these obesity treatment, intervention, and management
options.
 
PRIOR LEGISLATIVE HISTORY:

New bill.

 
FISCAL IMPLICATIONS:

To be determined.

 
EFFECTIVE DATE:
This act shall take effect one hundred eighty days after it shall have
become law.

2023-S8959 (ACTIVE) - Bill Text download pdf

                             
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                   8959
 
                             I N  S E N A T E
 
                               April 3, 2024
                                ___________
 
 Introduced  by  Sen.  COONEY -- read twice and ordered printed, and when
   printed to be committed to the Committee on Health
 
 AN ACT to amend the social  services  law  and  the  insurance  law,  in
   relation to requiring comprehensive coverage for treatment of obesity
 
   THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
 BLY, DO ENACT AS FOLLOWS:

   Section 1. Subdivision 2 of section 365-a of the social  services  law
 is amended by adding a new paragraph (nn) to read as follows:
   (NN)  (I) COMPREHENSIVE COVERAGE FOR TREATMENT OF OBESITY, WHICH SHALL
 INCLUDE COVERAGE FOR  PREVENTION  AND  WELLNESS,  NUTRITION  COUNSELING,
 INTENSIVE  BEHAVIORAL THERAPY, BARIATRIC SURGERY, AND FDA-APPROVED ANTI-
 OBESITY MEDICATION. FOR PURPOSES OF THIS PARAGRAPH, "FDA-APPROVED  ANTI-
 OBESITY  MEDICATION"  SHALL  MEAN ANY MEDICATION APPROVED BY THE FEDERAL
 FOOD AND DRUG ADMINISTRATION  WITH  AN  INDICATION  FOR  CHRONIC  WEIGHT
 MANAGEMENT IN PATIENTS WITH OBESITY.
   (II)  COVERAGE  CRITERIA  FOR  FDA-APPROVED  ANTI-OBESITY  MEDICATIONS
 PROVIDED UNDER THIS PARAGRAPH SHALL NOT BE  MORE  RESTRICTIVE  THAN  THE
 FDA-APPROVED INDICATIONS FOR SUCH TREATMENTS.
   (III)  COVERAGE  UNDER  THIS  PARAGRAPH SHALL BE NEITHER DIFFERENT NOR
 SEPARATE FROM COVERAGE FOR ANY OTHER ILLNESS, CONDITION, OR DISORDER FOR
 PURPOSES OF DETERMINING DEDUCTIBLES, LIFETIME DOLLAR  LIMITS,  COPAYMENT
 AND  COINSURANCE  FACTORS,  AND BENEFIT YEAR MAXIMUM FOR DEDUCTIBLES AND
 COPAYMENT AND COINSURANCE FACTORS.
   (IV) NOTHING SHALL PRECLUDE THE UNDERTAKING OF UTILIZATION  MANAGEMENT
 TO  DETERMINE  THE MEDICAL NECESSITY FOR TREATMENT OF OBESITY UNDER THIS
 PARAGRAPH, PROVIDED THAT ALL SUCH APPROPRIATENESS AND MEDICAL  NECESSITY
 DETERMINATIONS  ARE  MADE IN THE SAME MANNER AS THOSE DETERMINATIONS ARE
 MADE FOR THE TREATMENT OF ANY  OTHER  ILLNESS,  CONDITION,  OR  DISORDER
 COVERED BY SUCH POLICY, CONTRACT, OR PLAN.
   (V)  THE DEPARTMENT SHALL PROVIDE NOTICE TO ELIGIBLE PERSONS REGARDING
 THE COVERAGE REQUIRED BY THIS PARAGRAPH. THE NOTICE SHALL BE IN  WRITING
 AND  SHALL BE PROMINENTLY POSITIONED IN ANY LITERATURE OR CORRESPONDENCE
 SENT TO MEMBERS AND SHALL BE TRANSMITTED TO MEMBERS WITHIN THE  CALENDAR
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.
                                                            LBD11933-03-4

 S. 8959                             2
 
 YEAR  WHEN  ANNUAL INFORMATION IS MADE AVAILABLE TO ELIGIBLE PERSONS, OR
 IN ANY OTHER MAILING OR COMMUNICATION TO ELIGIBLE PERSONS.
   § 2. Subsection (i) of section 3216 of the insurance law is amended by
 adding a new paragraph 39 to read as follows:
   (39)  (A) EVERY POLICY WHICH PROVIDES MEDICAL, MAJOR MEDICAL, OR SIMI-
 LAR COMPREHENSIVE-TYPE COVERAGE SHALL PROVIDE COMPREHENSIVE COVERAGE FOR
 TREATMENT OF OBESITY, WHICH SHALL INCLUDE COVERAGE  FOR  PREVENTION  AND
 WELLNESS,  NUTRITION COUNSELING, INTENSIVE BEHAVIORAL THERAPY, BARIATRIC
 SURGERY, AND FDA-APPROVED ANTI-OBESITY MEDICATION. FOR PURPOSES OF  THIS
 PARAGRAPH, "FDA-APPROVED ANTI-OBESITY MEDICATION" SHALL MEAN ANY MEDICA-
 TION  APPROVED BY THE FEDERAL FOOD AND DRUG ADMINISTRATION WITH AN INDI-
 CATION FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS WITH OBESITY.
   (B)  COVERAGE  CRITERIA  FOR  FDA-APPROVED  ANTI-OBESITY   MEDICATIONS
 PROVIDED  UNDER  THIS  PARAGRAPH  SHALL NOT BE MORE RESTRICTIVE THAN THE
 FDA-APPROVED INDICATIONS FOR THOSE TREATMENTS.
   (C) COVERAGE UNDER THIS PARAGRAPH SHALL NEITHER BE DIFFERENT NOR SEPA-
 RATE FROM COVERAGE FOR ANY OTHER ILLNESS,  CONDITION,  OR  DISORDER  FOR
 PURPOSES  OF  DETERMINING DEDUCTIBLES, LIFETIME DOLLAR LIMITS, COPAYMENT
 AND COINSURANCE FACTORS, AND BENEFIT YEAR MAXIMUM  FOR  DEDUCTIBLES  AND
 COPAYMENT AND COINSURANCE FACTORS.
   (D)  NOTHING  SHALL PRECLUDE THE UNDERTAKING OF UTILIZATION MANAGEMENT
 TO DETERMINE THE MEDICAL NECESSITY FOR TREATMENT OF OBESITY  UNDER  THIS
 PARAGRAPH,  PROVIDED THAT ALL SUCH APPROPRIATENESS AND MEDICAL NECESSITY
 DETERMINATIONS ARE MADE IN THE SAME MANNER AS THOSE  DETERMINATIONS  ARE
 MADE  FOR  THE  TREATMENT  OF  ANY OTHER ILLNESS, CONDITION, OR DISORDER
 COVERED BY SUCH POLICY, CONTRACT, OR PLAN.
   (E) THE INSURER SHALL PROVIDE NOTICE TO COVERED PERSONS REGARDING  THE
 COVERAGE  REQUIRED BY THIS PARAGRAPH. THE NOTICE SHALL BE IN WRITING AND
 SHALL BE PROMINENTLY POSITIONED IN ANY LITERATURE OR CORRESPONDENCE SENT
 TO MEMBERS AND SHALL BE TRANSMITTED TO MEMBERS WITHIN THE CALENDAR  YEAR
 WHEN  ANNUAL INFORMATION IS MADE AVAILABLE TO COVERED PERSONS, OR IN ANY
 OTHER MAILING OR COMMUNICATION TO COVERED PERSONS.
   § 3. Subsection (l) of section 3221 of the insurance law is amended by
 adding a new paragraph 22 to read as follows:
   (22) (A) EVERY INSURER DELIVERING A GROUP OR BLANKET POLICY FOR DELIV-
 ERY IN THIS STATE THAT  PROVIDES  MEDICAL,  MAJOR  MEDICAL,  OR  SIMILAR
 COMPREHENSIVE-TYPE  COVERAGE  SHALL  PROVIDE  COMPREHENSIVE COVERAGE FOR
 TREATMENT OF OBESITY, WHICH SHALL INCLUDE COVERAGE  FOR  PREVENTION  AND
 WELLNESS,  NUTRITION COUNSELING, INTENSIVE BEHAVIORAL THERAPY, BARIATRIC
 SURGERY, AND FDA-APPROVED ANTI-OBESITY MEDICATION. FOR PURPOSES OF  THIS
 PARAGRAPH, "FDA-APPROVED ANTI-OBESITY MEDICATION" SHALL MEAN ANY MEDICA-
 TION  APPROVED BY THE FEDERAL FOOD AND DRUG ADMINISTRATION WITH AN INDI-
 CATION FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS WITH OBESITY.
   (B)  COVERAGE  CRITERIA  FOR  FDA-APPROVED  ANTI-OBESITY   MEDICATIONS
 PROVIDED  UNDER  THIS  PARAGRAPH  SHALL NOT BE MORE RESTRICTIVE THAN THE
 FDA-APPROVED INDICATIONS FOR THOSE TREATMENTS.
   (C) COVERAGE UNDER THIS PARAGRAPH SHALL NEITHER BE DIFFERENT NOR SEPA-
 RATE FROM COVERAGE FOR ANY OTHER ILLNESS,  CONDITION,  OR  DISORDER  FOR
 PURPOSES  OF  DETERMINING DEDUCTIBLES, LIFETIME DOLLAR LIMITS, COPAYMENT
 AND COINSURANCE FACTORS, AND BENEFIT YEAR MAXIMUM  FOR  DEDUCTIBLES  AND
 COPAYMENT AND COINSURANCE FACTORS.
   (D)  NOTHING  SHALL PRECLUDE THE UNDERTAKING OF UTILIZATION MANAGEMENT
 TO DETERMINE THE MEDICAL NECESSITY FOR TREATMENT OF OBESITY  UNDER  THIS
 PARAGRAPH,  PROVIDED THAT ALL SUCH APPROPRIATENESS AND MEDICAL NECESSITY
 DETERMINATIONS ARE MADE IN THE SAME MANNER AS THOSE  DETERMINATIONS  ARE
 S. 8959                             3

 MADE  FOR  THE  TREATMENT  OF  ANY OTHER ILLNESS, CONDITION, OR DISORDER
 COVERED BY SUCH POLICY, CONTRACT, OR PLAN.
   (E)  THE INSURER SHALL PROVIDE NOTICE TO COVERED PERSONS REGARDING THE
 COVERAGE REQUIRED BY THIS PARAGRAPH. THE NOTICE SHALL BE IN WRITING  AND
 SHALL BE PROMINENTLY POSITIONED IN ANY LITERATURE OR CORRESPONDENCE SENT
 TO  MEMBERS AND SHALL BE TRANSMITTED TO MEMBERS WITHIN THE CALENDAR YEAR
 WHEN ANNUAL INFORMATION IS MADE AVAILABLE TO COVERED PERSONS, OR IN  ANY
 OTHER MAILING OR COMMUNICATION TO COVERED PERSONS.
   §  4.  Section  4303  of  the insurance law is amended by adding a new
 subsection (vv) to read as follows:
   (VV) (1) EVERY POLICY WHICH PROVIDES MEDICAL, MAJOR MEDICAL, OR  SIMI-
 LAR COMPREHENSIVE-TYPE COVERAGE SHALL PROVIDE COMPREHENSIVE COVERAGE FOR
 TREATMENT  OF  OBESITY,  WHICH SHALL INCLUDE COVERAGE FOR PREVENTION AND
 WELLNESS, NUTRITION COUNSELING, INTENSIVE BEHAVIORAL THERAPY,  BARIATRIC
 SURGERY,  AND FDA-APPROVED ANTI-OBESITY MEDICATION. FOR PURPOSES OF THIS
 SUBSECTION, "FDA-APPROVED ANTI-OBESITY MEDICATION" SHALL MEAN ANY  MEDI-
 CATION  APPROVED  BY  THE  FEDERAL  FOOD AND DRUG ADMINISTRATION WITH AN
 INDICATION FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS WITH OBESITY.
   (2)  COVERAGE  CRITERIA  FOR  FDA-APPROVED  ANTI-OBESITY   MEDICATIONS
 PROVIDED  UNDER  THIS  SUBSECTION SHALL NOT BE MORE RESTRICTIVE THAN THE
 FDA-APPROVED INDICATIONS FOR THOSE TREATMENTS.
   (3) COVERAGE UNDER THIS SUBSECTION  SHALL  NEITHER  BE  DIFFERENT  NOR
 SEPARATE FROM COVERAGE FOR ANY OTHER ILLNESS, CONDITION, OR DISORDER FOR
 PURPOSES  OF  DETERMINING DEDUCTIBLES, LIFETIME DOLLAR LIMITS, COPAYMENT
 AND COINSURANCE FACTORS, AND BENEFIT YEAR MAXIMUM  FOR  DEDUCTIBLES  AND
 COPAYMENT AND COINSURANCE FACTORS.
   (4)  NOTHING  SHALL PRECLUDE THE UNDERTAKING OF UTILIZATION MANAGEMENT
 TO DETERMINE THE MEDICAL NECESSITY FOR TREATMENT OF OBESITY  UNDER  THIS
 SUBSECTION, PROVIDED THAT ALL SUCH APPROPRIATENESS AND MEDICAL NECESSITY
 DETERMINATIONS  ARE  MADE IN THE SAME MANNER AS THOSE DETERMINATIONS ARE
 MADE FOR THE TREATMENT OF ANY  OTHER  ILLNESS,  CONDITION,  OR  DISORDER
 COVERED BY SUCH POLICY, CONTRACT, OR PLAN.
   (5)  THE INSURER SHALL PROVIDE NOTICE TO COVERED PERSONS REGARDING THE
 COVERAGE REQUIRED BY THIS SUBSECTION. THE NOTICE SHALL BE IN WRITING AND
 SHALL BE PROMINENTLY POSITIONED IN ANY LITERATURE OR CORRESPONDENCE SENT
 TO MEMBERS AND SHALL BE TRANSMITTED TO MEMBERS WITHIN THE CALENDAR  YEAR
 WHEN  ANNUAL INFORMATION IS MADE AVAILABLE TO COVERED PERSONS, OR IN ANY
 OTHER MAILING OR COMMUNICATION TO COVERED PERSONS.
   § 5. This act shall take effect on the one hundred eightieth day after
 it shall have become a law and shall apply to any policy issued,  deliv-
 ered,  renewed,  and/or  modified on or after the effective date of this
 act.

Comments

Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.

Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.

Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Senate Bill S8959

Sponsored By

Current Bill Status - In Senate Committee Health Committee

2023-S8959 (ACTIVE) - Details

2023-S8959 (ACTIVE) - Summary

2023-S8959 (ACTIVE) - Sponsor Memo

2023-S8959 (ACTIVE) - Bill Text download pdf

Comments

Senate Bill S8959

Share this bill

Sponsored By

Jeremy A. Cooney

Current Bill Status - In Senate Committee Health Committee

2023-S8959 (ACTIVE) - Details

2023-S8959 (ACTIVE) - Summary

2023-S8959 (ACTIVE) - Sponsor Memo

2023-S8959 (ACTIVE) - Bill Text download pdf

Comments